POPULARITY
4 episodes with r r aml
4 episodes with r r aml
4 episodes with r r aml
3 episodes with r r aml
3 episodes with r r aml
3 episodes with r r aml
4 episodes with r r aml
3 episodes with r r aml
In this episode, listen to Professor Eunice S. Wang, MD, share her clinical insights and takeaways on new data for acute myeloid leukemia (AML) presented at the 2024 ASCO annual meeting and the EHA 2024 Congress including:Data from the prospective, single-center phase Ib/II study of FLAG-IDA plus venetoclax in newly diagnosed or relapsed/refractory AML Phase I/II study of oral decitabine/cedazuridine with venetoclax and gilteritinib in patients with newly diagnosed and relapsed/refractory FLT3-mutant AMLA retrospective comparison of abbreviated course 7+7 vs standard HMA plus venetoclax doublet in older/unfit patients with newly diagnosed AML Multisite randomized trial of a collaborative palliative and oncology care model for patients with AML and myelodysplastic syndromes (MDS) receiving nonintensive therapyFinal 5-year results from the phase II pivotal cohort of olutasidenib for IDH1-mutated AML Post hoc analyses of outcomes in patients with AML and MDS-related changes who received oral azacitidine maintenance therapy in the phase III QUAZAR AML-001 studyFirst-in-human phase I/II of the menin-MLL inhibitor DSP-5336 in patients with R/R acute leukemia: updated results from the dose escalation phase A phase Ib study of the menin-KMT2A inhibitor bleximenib in combination with venetoclax and azacitidine in R/R AML with alterations in KMT2A or NPM1 Program faculty:Eunice S. Wang, MDChief, Leukemia and Benign Hematology ServiceProfessor of OncologyRoswell Park Comprehensive Cancer CenterBuffalo, New YorkCourtney DiNardo, MD, MSCEProfessor of MedicineDepartment of LeukemiaMD Anderson Cancer CenterHouston, TexasResources:To download the slides associated with this podcast discussion, please visit the program page:https://bit.ly/4bvJGij
Go online to PeerView.com/HGR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In recent years, the “circle” of personalized disease management for acute myeloid leukemia (AML) has been expanded, and clinicians are now able to utilize innovative therapeutics, such as novel cytotoxic platforms, targeted agents, immunotherapy, and epigenetic approaches, that can be tailored to patients' diverse medical needs. This Clinical Consults activity pairs rapid-fire, case-based discussions with mini lecture sessions wherein the experts support their treatment recommendations by presenting the evidence that supports the use of cutting-edge therapeutics—including newer FLT3 inhibitors, chemo-free targeted platforms, epigenetic agents, and emerging antibody platforms —in various AML settings. Join the experts and learn how you can successfully “expand the circle” of personalized care in AML! Upon completion of this activity, participants should be better able to: Cite baseline factors such as age, comorbidities, functional status, and cytogenetic/mutational findings that can inform personalized treatment selection in AML; Describe evidence supporting the personalized use of newer cytotoxic platforms, targeted agents, immunotherapy, radioimmunoconjugates, and epigenetic strategies as upfront treatment, maintenance therapy, or in the management of R/R AML; Develop personalized team-based management protocols for AML that integrate newer treatment modalities based on the presence or absence of targetable mutations, functional status, treatment setting, or subtype; and Manage optimized dosing, response monitoring, and safety considerations when using modern therapeutic platforms in the AML setting.
Go online to PeerView.com/HGR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In recent years, the “circle” of personalized disease management for acute myeloid leukemia (AML) has been expanded, and clinicians are now able to utilize innovative therapeutics, such as novel cytotoxic platforms, targeted agents, immunotherapy, and epigenetic approaches, that can be tailored to patients' diverse medical needs. This Clinical Consults activity pairs rapid-fire, case-based discussions with mini lecture sessions wherein the experts support their treatment recommendations by presenting the evidence that supports the use of cutting-edge therapeutics—including newer FLT3 inhibitors, chemo-free targeted platforms, epigenetic agents, and emerging antibody platforms —in various AML settings. Join the experts and learn how you can successfully “expand the circle” of personalized care in AML! Upon completion of this activity, participants should be better able to: Cite baseline factors such as age, comorbidities, functional status, and cytogenetic/mutational findings that can inform personalized treatment selection in AML; Describe evidence supporting the personalized use of newer cytotoxic platforms, targeted agents, immunotherapy, radioimmunoconjugates, and epigenetic strategies as upfront treatment, maintenance therapy, or in the management of R/R AML; Develop personalized team-based management protocols for AML that integrate newer treatment modalities based on the presence or absence of targetable mutations, functional status, treatment setting, or subtype; and Manage optimized dosing, response monitoring, and safety considerations when using modern therapeutic platforms in the AML setting.
Go online to PeerView.com/HGR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In recent years, the “circle” of personalized disease management for acute myeloid leukemia (AML) has been expanded, and clinicians are now able to utilize innovative therapeutics, such as novel cytotoxic platforms, targeted agents, immunotherapy, and epigenetic approaches, that can be tailored to patients' diverse medical needs. This Clinical Consults activity pairs rapid-fire, case-based discussions with mini lecture sessions wherein the experts support their treatment recommendations by presenting the evidence that supports the use of cutting-edge therapeutics—including newer FLT3 inhibitors, chemo-free targeted platforms, epigenetic agents, and emerging antibody platforms —in various AML settings. Join the experts and learn how you can successfully “expand the circle” of personalized care in AML! Upon completion of this activity, participants should be better able to: Cite baseline factors such as age, comorbidities, functional status, and cytogenetic/mutational findings that can inform personalized treatment selection in AML; Describe evidence supporting the personalized use of newer cytotoxic platforms, targeted agents, immunotherapy, radioimmunoconjugates, and epigenetic strategies as upfront treatment, maintenance therapy, or in the management of R/R AML; Develop personalized team-based management protocols for AML that integrate newer treatment modalities based on the presence or absence of targetable mutations, functional status, treatment setting, or subtype; and Manage optimized dosing, response monitoring, and safety considerations when using modern therapeutic platforms in the AML setting.
Go online to PeerView.com/HGR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In recent years, the “circle” of personalized disease management for acute myeloid leukemia (AML) has been expanded, and clinicians are now able to utilize innovative therapeutics, such as novel cytotoxic platforms, targeted agents, immunotherapy, and epigenetic approaches, that can be tailored to patients' diverse medical needs. This Clinical Consults activity pairs rapid-fire, case-based discussions with mini lecture sessions wherein the experts support their treatment recommendations by presenting the evidence that supports the use of cutting-edge therapeutics—including newer FLT3 inhibitors, chemo-free targeted platforms, epigenetic agents, and emerging antibody platforms —in various AML settings. Join the experts and learn how you can successfully “expand the circle” of personalized care in AML! Upon completion of this activity, participants should be better able to: Cite baseline factors such as age, comorbidities, functional status, and cytogenetic/mutational findings that can inform personalized treatment selection in AML; Describe evidence supporting the personalized use of newer cytotoxic platforms, targeted agents, immunotherapy, radioimmunoconjugates, and epigenetic strategies as upfront treatment, maintenance therapy, or in the management of R/R AML; Develop personalized team-based management protocols for AML that integrate newer treatment modalities based on the presence or absence of targetable mutations, functional status, treatment setting, or subtype; and Manage optimized dosing, response monitoring, and safety considerations when using modern therapeutic platforms in the AML setting.
Go online to PeerView.com/HGR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In recent years, the “circle” of personalized disease management for acute myeloid leukemia (AML) has been expanded, and clinicians are now able to utilize innovative therapeutics, such as novel cytotoxic platforms, targeted agents, immunotherapy, and epigenetic approaches, that can be tailored to patients' diverse medical needs. This Clinical Consults activity pairs rapid-fire, case-based discussions with mini lecture sessions wherein the experts support their treatment recommendations by presenting the evidence that supports the use of cutting-edge therapeutics—including newer FLT3 inhibitors, chemo-free targeted platforms, epigenetic agents, and emerging antibody platforms —in various AML settings. Join the experts and learn how you can successfully “expand the circle” of personalized care in AML! Upon completion of this activity, participants should be better able to: Cite baseline factors such as age, comorbidities, functional status, and cytogenetic/mutational findings that can inform personalized treatment selection in AML; Describe evidence supporting the personalized use of newer cytotoxic platforms, targeted agents, immunotherapy, radioimmunoconjugates, and epigenetic strategies as upfront treatment, maintenance therapy, or in the management of R/R AML; Develop personalized team-based management protocols for AML that integrate newer treatment modalities based on the presence or absence of targetable mutations, functional status, treatment setting, or subtype; and Manage optimized dosing, response monitoring, and safety considerations when using modern therapeutic platforms in the AML setting.
Go online to PeerView.com/HGR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In recent years, the “circle” of personalized disease management for acute myeloid leukemia (AML) has been expanded, and clinicians are now able to utilize innovative therapeutics, such as novel cytotoxic platforms, targeted agents, immunotherapy, and epigenetic approaches, that can be tailored to patients' diverse medical needs. This Clinical Consults activity pairs rapid-fire, case-based discussions with mini lecture sessions wherein the experts support their treatment recommendations by presenting the evidence that supports the use of cutting-edge therapeutics—including newer FLT3 inhibitors, chemo-free targeted platforms, epigenetic agents, and emerging antibody platforms —in various AML settings. Join the experts and learn how you can successfully “expand the circle” of personalized care in AML! Upon completion of this activity, participants should be better able to: Cite baseline factors such as age, comorbidities, functional status, and cytogenetic/mutational findings that can inform personalized treatment selection in AML; Describe evidence supporting the personalized use of newer cytotoxic platforms, targeted agents, immunotherapy, radioimmunoconjugates, and epigenetic strategies as upfront treatment, maintenance therapy, or in the management of R/R AML; Develop personalized team-based management protocols for AML that integrate newer treatment modalities based on the presence or absence of targetable mutations, functional status, treatment setting, or subtype; and Manage optimized dosing, response monitoring, and safety considerations when using modern therapeutic platforms in the AML setting.
Top 5 Most Read RNS's on Vox Markets for Friday 28th April 2023 1. Premier African Minerals #PREM - Director / PDMR shareholding Premier African Minerals Limited announces that on 27 April 2023, Mr George Roach, Chief Executive Officer and Mr. Wolfgang Hampel, Non-Executive Director, exercised options over in aggregate 24,500,000 new ordinary shares in the capital of the Company. 2. Argo Blockchain #ARB - 2022 Full Year Results Increased hashrate capacity by 55% from 1.6 EH/s at the end of 2021 to 2.5 EH/s at the end of 2022 Revenues of £47.4 million ($58.6 million), a decrease of 36% from 2021, driven primarily by a significant decrease in Bitcoin price and an increase in the global hashrate and associated network difficulty level Net loss of £194.2 million ($240.2 million), driven primarily by the change in fair value of digital assets, impairment of assets, and losses associated with our divestitures 3. AIM - Cancellation - Rambler Metals & Mining Plc Pursuant to aim rule 41 the following securities have been cancelled from trading on AIM with effect from the time and date of this notice. 4. Hemogenyx Pharma #HEMO - Final Results for the Year Ended 31 December 2022 Nearing completion of the IND application to the FDA to enter phase I clinical trials for HEMO-CAR-T for the treatment of R/R AML. CBR platform extended into treatment of multiple viral infections beyond COVID-19 using single CBR-based therapeutic. Losss before tax £3,986,982 Cash of £2,532,758 5. Union Jack Oil #UJO - Announcement by Reabold Resources PLC on PEDL183 Union Jack Oil notes today's announcement from Reabold Resources on PEDL183 in 2013. Union Jack holds 16.665% economic interest in PEDL183. PEDL 183 licence update: · JV partnership agreed specific well path for West Newton B-2 well · Potentially highly significant discovery in Crawberry Hill, part of the PEDL 183 licence and previously drilled by Rathlin Energy Limited ("Rathlin") in 2013
In this episode, we are joined by Dr. Jill Lykon, Clinical Pharmacist Specialist in Hematology at the University of Miami, to discuss the use of IDH inhibitors in relapsed/refractory AML. How do we choose between IDH inhibitors? Is "Olu" the new standard IDH inhibitor in R/R AML, or just the name of a drunk snowman? What about ivosidenib? Olutasidenib Phase I - Watts, et al. Lancet. 2023: https://pubmed.ncbi.nlm.nih.gov/36370742/ Olutasidenib Phase II ASH Abstract: https://ash.confex.com/ash/2022/webprogram/Paper167330.html Ivosidenib Phase I escalation/expansion - Dinardo, et al. NEJM. 2018: https://pubmed.ncbi.nlm.nih.gov/29860938/ Design of olutasidenib and other IDH inhibitors: https://pubmed.ncbi.nlm.nih.gov/31971798/ and https://pubmed.ncbi.nlm.nih.gov/36091829/ Episode 5 of WolverHeme Happy Hour (for background on IDH Inhibitors and frontline data): https://open.spotify.com/episode/4eNXjuGEFFRWTFJF0zsuMw?si=9bd0ae0a488e44ba
Listen to a blog summary of a trending research paper published by Oncotarget: "Anti-tumor effect of antibody drug conjugate ASP1235 targeting Fms-like tyrosine kinase 3 with venetoclax plus azacitidine in an acute myeloid leukemia xenograft mouse model." _________________________________________________________ The average age of patients with acute myeloid leukemia (AML) is 67 years old. Older adults generally have a lower tolerance for treatments that exhibit high off-target toxicity. Additionally, chemotherapy-relapsed or -refractory (R/R) AML patients are often at an advanced stage of disease and are therefore more likely to have comorbidities that may reduce their tolerance for harsh treatments. Thus, pharmaceutical AML drugs with high efficacy and low toxicity are in high demand. Antibody drug conjugates (ADCs) are emerging as promising therapeutic approaches to more safely treat hematological malignancies by reducing side effects. ADCs are designed to decrease damage to healthy tissues by specifically targeting tumor-associated antigens attached to cancer cells. “Antibody drug conjugates (ADC) are one of the modalities that aims to dissociate drug efficacy from toxicity. ADC consists of three components: antibody specific for tumor associated antigen, drug linker and cytotoxic payload.” ASTELLAS PHARMA Recently, researchers from Astellas Pharma Inc. (a pharmaceutical company in Japan) developed ASP1235—a novel ADC that targets Fms-like tyrosine kinase 3 (FLT3). In more than 90% of AML patients, FLT3 is overexpressed on leukemic blasts. ASP1235 is designed to target FLT3-positive leukemia cells and deliver the cytotoxic drug payload to these cells. However, this drug alone was found to have only a mild effect on AML cells, prompting researchers to assess the efficacy of ASP1235 in combination with other drugs. In a new study, Astellas Pharma researchers Hirofumi Tsuzuki, Tatsuya Kawase, Taisuke Nakazawa, Masamichi Mori, and Taku Yoshida investigated the efficacy of ASP1235 combined with venetoclax (an anti-apoptotic agent) and azacitidine (a DNA methyltransferase inhibitor) in an experimental mouse model of AML. Their research paper was published in Oncotarget on December 20, 2022, and entitled, “Anti-tumor effect of antibody drug conjugate ASP1235 targeting Fms-like tyrosine kinase 3 with venetoclax plus azacitidine in an acute myeloid leukemia xenograft mouse model.” Full blog: https://www.oncotarget.org/2023/01/04/novel-antibody-drug-conjugate-improves-murine-acute-myeloid-leukemia/ DOI: https://doi.org/10.18632/oncotarget.28331 Corresponding author: Hirofumi Tsuzuki - hirofumi.tsuzuki@astellas.com Keywords: acute myeloid leukemia (AML), ASP1235, antibody drug conjugate (ADC), venetoclax, azacitidine About Oncotarget Oncotarget is a primarily oncology-focused, peer-reviewed, open access journal. Papers are published continuously within yearly volumes in their final and complete form, and then quickly released to Pubmed. On September 15, 2022, Oncotarget was accepted again for indexing by MEDLINE. Oncotarget is now indexed by Medline/PubMed and PMC/PubMed. To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: SoundCloud - https://soundcloud.com/oncotarget Facebook - https://www.facebook.com/Oncotarget/ Twitter - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/OncotargetYouTube LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Media Contact MEDIA@IMPACTJOURNALS.COM 18009220957
Featuring a slide presentation and related discussion from Dr Eytan Stein, including the following topics: Historical paradigms for treating newly diagnosed acute myeloid leukemia (AML) (0:00) Long-term findings and emerging results with venetoclax-based therapies for newly diagnosed and relapsed/refractory (R/R) AML (1:19) Efficacy and tolerability of oral decitabine/cedazuridine for patients with AML (19:27) Mechanism of action, activity and safety of magrolimab-based therapies for newly diagnosed and R/R disease (23:34) Sabatolimab: Mechanism of action and efficacy in combination with a hypomethylating agent (32:01) Therapeutic targeting of Menin and NPM1 mutations in AML; activity of entospletinib in combination with induction chemotherapy (37:29) CME information and select publications
Go online to PeerView.com/NQY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you up on the most recent therapeutic breakthroughs for personalized care in acute myeloid leukemia (AML)? PeerView's latest Clinical Consults AML program, based on a live event, brings you insights from experts on the power of modern personalized medicine. Using case-based examples and the latest data, the experts will demonstrate how to integrate novel intensive therapies, targeted agents, and maintenance strategies into clinical management while showcasing best practices from leading cancer centers to provide guidance on how innovative therapies can be safely used to re-invent AML management protocols. Upon completion of this activity, participants should be better able to: Cite updated clinical findings on novel cytotoxic, targeted, epigenetic, and immune-based strategies (including combination therapies) with applications in acute myeloid leukemia (AML) care—including in the newly diagnosed (ND), post-remission maintenance, or relapsed/refractory (R/R) settings; Incorporate novel therapeutics into personalized, team-based management of ND and R/R AML based on factors such as age, fitness, treatment history, depth of response, HCT eligibility, and the presence or absence of genetic/molecular features; Develop team-based strategies to address the unique suite of adverse events associated with the use of novel therapeutics for AML
Go online to PeerView.com/NQY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you up on the most recent therapeutic breakthroughs for personalized care in acute myeloid leukemia (AML)? PeerView's latest Clinical Consults AML program, based on a live event, brings you insights from experts on the power of modern personalized medicine. Using case-based examples and the latest data, the experts will demonstrate how to integrate novel intensive therapies, targeted agents, and maintenance strategies into clinical management while showcasing best practices from leading cancer centers to provide guidance on how innovative therapies can be safely used to re-invent AML management protocols. Upon completion of this activity, participants should be better able to: Cite updated clinical findings on novel cytotoxic, targeted, epigenetic, and immune-based strategies (including combination therapies) with applications in acute myeloid leukemia (AML) care—including in the newly diagnosed (ND), post-remission maintenance, or relapsed/refractory (R/R) settings; Incorporate novel therapeutics into personalized, team-based management of ND and R/R AML based on factors such as age, fitness, treatment history, depth of response, HCT eligibility, and the presence or absence of genetic/molecular features; Develop team-based strategies to address the unique suite of adverse events associated with the use of novel therapeutics for AML
Go online to PeerView.com/NQY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you up on the most recent therapeutic breakthroughs for personalized care in acute myeloid leukemia (AML)? PeerView's latest Clinical Consults AML program, based on a live event, brings you insights from experts on the power of modern personalized medicine. Using case-based examples and the latest data, the experts will demonstrate how to integrate novel intensive therapies, targeted agents, and maintenance strategies into clinical management while showcasing best practices from leading cancer centers to provide guidance on how innovative therapies can be safely used to re-invent AML management protocols. Upon completion of this activity, participants should be better able to: Cite updated clinical findings on novel cytotoxic, targeted, epigenetic, and immune-based strategies (including combination therapies) with applications in acute myeloid leukemia (AML) care—including in the newly diagnosed (ND), post-remission maintenance, or relapsed/refractory (R/R) settings; Incorporate novel therapeutics into personalized, team-based management of ND and R/R AML based on factors such as age, fitness, treatment history, depth of response, HCT eligibility, and the presence or absence of genetic/molecular features; Develop team-based strategies to address the unique suite of adverse events associated with the use of novel therapeutics for AML
Go online to PeerView.com/NQY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you up on the most recent therapeutic breakthroughs for personalized care in acute myeloid leukemia (AML)? PeerView's latest Clinical Consults AML program, based on a live event, brings you insights from experts on the power of modern personalized medicine. Using case-based examples and the latest data, the experts will demonstrate how to integrate novel intensive therapies, targeted agents, and maintenance strategies into clinical management while showcasing best practices from leading cancer centers to provide guidance on how innovative therapies can be safely used to re-invent AML management protocols. Upon completion of this activity, participants should be better able to: Cite updated clinical findings on novel cytotoxic, targeted, epigenetic, and immune-based strategies (including combination therapies) with applications in acute myeloid leukemia (AML) care—including in the newly diagnosed (ND), post-remission maintenance, or relapsed/refractory (R/R) settings; Incorporate novel therapeutics into personalized, team-based management of ND and R/R AML based on factors such as age, fitness, treatment history, depth of response, HCT eligibility, and the presence or absence of genetic/molecular features; Develop team-based strategies to address the unique suite of adverse events associated with the use of novel therapeutics for AML
Go online to PeerView.com/NQY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you up on the most recent therapeutic breakthroughs for personalized care in acute myeloid leukemia (AML)? PeerView's latest Clinical Consults AML program, based on a live event, brings you insights from experts on the power of modern personalized medicine. Using case-based examples and the latest data, the experts will demonstrate how to integrate novel intensive therapies, targeted agents, and maintenance strategies into clinical management while showcasing best practices from leading cancer centers to provide guidance on how innovative therapies can be safely used to re-invent AML management protocols. Upon completion of this activity, participants should be better able to: Cite updated clinical findings on novel cytotoxic, targeted, epigenetic, and immune-based strategies (including combination therapies) with applications in acute myeloid leukemia (AML) care—including in the newly diagnosed (ND), post-remission maintenance, or relapsed/refractory (R/R) settings; Incorporate novel therapeutics into personalized, team-based management of ND and R/R AML based on factors such as age, fitness, treatment history, depth of response, HCT eligibility, and the presence or absence of genetic/molecular features; Develop team-based strategies to address the unique suite of adverse events associated with the use of novel therapeutics for AML
Go online to PeerView.com/NQY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you up on the most recent therapeutic breakthroughs for personalized care in acute myeloid leukemia (AML)? PeerView's latest Clinical Consults AML program, based on a live event, brings you insights from experts on the power of modern personalized medicine. Using case-based examples and the latest data, the experts will demonstrate how to integrate novel intensive therapies, targeted agents, and maintenance strategies into clinical management while showcasing best practices from leading cancer centers to provide guidance on how innovative therapies can be safely used to re-invent AML management protocols. Upon completion of this activity, participants should be better able to: Cite updated clinical findings on novel cytotoxic, targeted, epigenetic, and immune-based strategies (including combination therapies) with applications in acute myeloid leukemia (AML) care—including in the newly diagnosed (ND), post-remission maintenance, or relapsed/refractory (R/R) settings; Incorporate novel therapeutics into personalized, team-based management of ND and R/R AML based on factors such as age, fitness, treatment history, depth of response, HCT eligibility, and the presence or absence of genetic/molecular features; Develop team-based strategies to address the unique suite of adverse events associated with the use of novel therapeutics for AML
Go online to PeerView.com/NVX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The rapid validation of novel cytotoxic, targeted, and epigenetic treatment approaches in acute myeloid leukemia (AML) has quickly augmented—and in some cases, eclipsed—long-standing options centered around standard cytarabine-based regimens. These developments have afforded clinicians the opportunity to develop truly personalized treatment protocols designed to overcome therapeutic challenges in different AML populations. This activity will prepare learners for the increasingly personalized management of AML through a series of case-based, expert-led conversations on modern AML care. The panelists discuss topics such as the changing nature of upfront therapy, the challenges of selecting postremission maintenance, and new developments in selecting evidence-based therapy for R/R AML. Learn how to skillfully deploy novel therapeutics in AML—watch today! Upon completion of this activity, participants should be better able to: Cite current evidence for novel cytotoxic, targeted, epigenetic, and immune-based strategies (including combination therapies) with applications in AML care, including in the newly diagnosed, postremission maintenance, or relapsed/refractory settings; Integrate novel cytotoxic, antibody, epigenetic, or targeted strategies into personalized treatment plans for AML patients based on factors such as age and fitness; the presence of TP53, FLT3, and IDH mutations; MLL rearrangements; and treatment history prior to relapse; and Implement management protocols to address the unique suite of adverse events associated with the use of novel therapeutics for AML.
Go online to PeerView.com/NVX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The rapid validation of novel cytotoxic, targeted, and epigenetic treatment approaches in acute myeloid leukemia (AML) has quickly augmented—and in some cases, eclipsed—long-standing options centered around standard cytarabine-based regimens. These developments have afforded clinicians the opportunity to develop truly personalized treatment protocols designed to overcome therapeutic challenges in different AML populations. This activity will prepare learners for the increasingly personalized management of AML through a series of case-based, expert-led conversations on modern AML care. The panelists discuss topics such as the changing nature of upfront therapy, the challenges of selecting postremission maintenance, and new developments in selecting evidence-based therapy for R/R AML. Learn how to skillfully deploy novel therapeutics in AML—watch today! Upon completion of this activity, participants should be better able to: Cite current evidence for novel cytotoxic, targeted, epigenetic, and immune-based strategies (including combination therapies) with applications in AML care, including in the newly diagnosed, postremission maintenance, or relapsed/refractory settings; Integrate novel cytotoxic, antibody, epigenetic, or targeted strategies into personalized treatment plans for AML patients based on factors such as age and fitness; the presence of TP53, FLT3, and IDH mutations; MLL rearrangements; and treatment history prior to relapse; and Implement management protocols to address the unique suite of adverse events associated with the use of novel therapeutics for AML.
Go online to PeerView.com/NVX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The rapid validation of novel cytotoxic, targeted, and epigenetic treatment approaches in acute myeloid leukemia (AML) has quickly augmented—and in some cases, eclipsed—long-standing options centered around standard cytarabine-based regimens. These developments have afforded clinicians the opportunity to develop truly personalized treatment protocols designed to overcome therapeutic challenges in different AML populations. This activity will prepare learners for the increasingly personalized management of AML through a series of case-based, expert-led conversations on modern AML care. The panelists discuss topics such as the changing nature of upfront therapy, the challenges of selecting postremission maintenance, and new developments in selecting evidence-based therapy for R/R AML. Learn how to skillfully deploy novel therapeutics in AML—watch today! Upon completion of this activity, participants should be better able to: Cite current evidence for novel cytotoxic, targeted, epigenetic, and immune-based strategies (including combination therapies) with applications in AML care, including in the newly diagnosed, postremission maintenance, or relapsed/refractory settings; Integrate novel cytotoxic, antibody, epigenetic, or targeted strategies into personalized treatment plans for AML patients based on factors such as age and fitness; the presence of TP53, FLT3, and IDH mutations; MLL rearrangements; and treatment history prior to relapse; and Implement management protocols to address the unique suite of adverse events associated with the use of novel therapeutics for AML.
Go online to PeerView.com/NVX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The rapid validation of novel cytotoxic, targeted, and epigenetic treatment approaches in acute myeloid leukemia (AML) has quickly augmented—and in some cases, eclipsed—long-standing options centered around standard cytarabine-based regimens. These developments have afforded clinicians the opportunity to develop truly personalized treatment protocols designed to overcome therapeutic challenges in different AML populations. This activity will prepare learners for the increasingly personalized management of AML through a series of case-based, expert-led conversations on modern AML care. The panelists discuss topics such as the changing nature of upfront therapy, the challenges of selecting postremission maintenance, and new developments in selecting evidence-based therapy for R/R AML. Learn how to skillfully deploy novel therapeutics in AML—watch today! Upon completion of this activity, participants should be better able to: Cite current evidence for novel cytotoxic, targeted, epigenetic, and immune-based strategies (including combination therapies) with applications in AML care, including in the newly diagnosed, postremission maintenance, or relapsed/refractory settings; Integrate novel cytotoxic, antibody, epigenetic, or targeted strategies into personalized treatment plans for AML patients based on factors such as age and fitness; the presence of TP53, FLT3, and IDH mutations; MLL rearrangements; and treatment history prior to relapse; and Implement management protocols to address the unique suite of adverse events associated with the use of novel therapeutics for AML.
Go online to PeerView.com/NVX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The rapid validation of novel cytotoxic, targeted, and epigenetic treatment approaches in acute myeloid leukemia (AML) has quickly augmented—and in some cases, eclipsed—long-standing options centered around standard cytarabine-based regimens. These developments have afforded clinicians the opportunity to develop truly personalized treatment protocols designed to overcome therapeutic challenges in different AML populations. This activity will prepare learners for the increasingly personalized management of AML through a series of case-based, expert-led conversations on modern AML care. The panelists discuss topics such as the changing nature of upfront therapy, the challenges of selecting postremission maintenance, and new developments in selecting evidence-based therapy for R/R AML. Learn how to skillfully deploy novel therapeutics in AML—watch today! Upon completion of this activity, participants should be better able to: Cite current evidence for novel cytotoxic, targeted, epigenetic, and immune-based strategies (including combination therapies) with applications in AML care, including in the newly diagnosed, postremission maintenance, or relapsed/refractory settings; Integrate novel cytotoxic, antibody, epigenetic, or targeted strategies into personalized treatment plans for AML patients based on factors such as age and fitness; the presence of TP53, FLT3, and IDH mutations; MLL rearrangements; and treatment history prior to relapse; and Implement management protocols to address the unique suite of adverse events associated with the use of novel therapeutics for AML.
Go online to PeerView.com/NVX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The rapid validation of novel cytotoxic, targeted, and epigenetic treatment approaches in acute myeloid leukemia (AML) has quickly augmented—and in some cases, eclipsed—long-standing options centered around standard cytarabine-based regimens. These developments have afforded clinicians the opportunity to develop truly personalized treatment protocols designed to overcome therapeutic challenges in different AML populations. This activity will prepare learners for the increasingly personalized management of AML through a series of case-based, expert-led conversations on modern AML care. The panelists discuss topics such as the changing nature of upfront therapy, the challenges of selecting postremission maintenance, and new developments in selecting evidence-based therapy for R/R AML. Learn how to skillfully deploy novel therapeutics in AML—watch today! Upon completion of this activity, participants should be better able to: Cite current evidence for novel cytotoxic, targeted, epigenetic, and immune-based strategies (including combination therapies) with applications in AML care, including in the newly diagnosed, postremission maintenance, or relapsed/refractory settings; Integrate novel cytotoxic, antibody, epigenetic, or targeted strategies into personalized treatment plans for AML patients based on factors such as age and fitness; the presence of TP53, FLT3, and IDH mutations; MLL rearrangements; and treatment history prior to relapse; and Implement management protocols to address the unique suite of adverse events associated with the use of novel therapeutics for AML.
Go online to PeerView.com/NVX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The rapid validation of novel cytotoxic, targeted, and epigenetic treatment approaches in acute myeloid leukemia (AML) has quickly augmented—and in some cases, eclipsed—long-standing options centered around standard cytarabine-based regimens. These developments have afforded clinicians the opportunity to develop truly personalized treatment protocols designed to overcome therapeutic challenges in different AML populations. This activity will prepare learners for the increasingly personalized management of AML through a series of case-based, expert-led conversations on modern AML care. The panelists discuss topics such as the changing nature of upfront therapy, the challenges of selecting postremission maintenance, and new developments in selecting evidence-based therapy for R/R AML. Learn how to skillfully deploy novel therapeutics in AML—watch today! Upon completion of this activity, participants should be better able to: Cite current evidence for novel cytotoxic, targeted, epigenetic, and immune-based strategies (including combination therapies) with applications in AML care, including in the newly diagnosed, postremission maintenance, or relapsed/refractory settings; Integrate novel cytotoxic, antibody, epigenetic, or targeted strategies into personalized treatment plans for AML patients based on factors such as age and fitness; the presence of TP53, FLT3, and IDH mutations; MLL rearrangements; and treatment history prior to relapse; and Implement management protocols to address the unique suite of adverse events associated with the use of novel therapeutics for AML.
Go online to PeerView.com/NVX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The rapid validation of novel cytotoxic, targeted, and epigenetic treatment approaches in acute myeloid leukemia (AML) has quickly augmented—and in some cases, eclipsed—long-standing options centered around standard cytarabine-based regimens. These developments have afforded clinicians the opportunity to develop truly personalized treatment protocols designed to overcome therapeutic challenges in different AML populations. This activity will prepare learners for the increasingly personalized management of AML through a series of case-based, expert-led conversations on modern AML care. The panelists discuss topics such as the changing nature of upfront therapy, the challenges of selecting postremission maintenance, and new developments in selecting evidence-based therapy for R/R AML. Learn how to skillfully deploy novel therapeutics in AML—watch today! Upon completion of this activity, participants should be better able to: Cite current evidence for novel cytotoxic, targeted, epigenetic, and immune-based strategies (including combination therapies) with applications in AML care, including in the newly diagnosed, postremission maintenance, or relapsed/refractory settings; Integrate novel cytotoxic, antibody, epigenetic, or targeted strategies into personalized treatment plans for AML patients based on factors such as age and fitness; the presence of TP53, FLT3, and IDH mutations; MLL rearrangements; and treatment history prior to relapse; and Implement management protocols to address the unique suite of adverse events associated with the use of novel therapeutics for AML.
Go online to PeerView.com/HJG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. New science has dramatically altered the current clinical consensus on personalized care for HCT-eligible AML patients and supported the use of a variety of options (depending on a patient's baseline characteristics). In this activity from the 2022 Tandem meetings, our expert panelists use a case-based format to tackle these new developments and provide instruction on how to integrate novel targeted, HMA, and antibody-based options into the management of HCT-eligible AML. Throughout, they provide insights on how to choose appropriate induction, conditioning, post-remission, and maintenance options, as well as discuss treatment plans for relapsed/refractory disease. Watch this program to see how novel therapeutics are changing paradigms and challenging long-standing practices in the management of HCT-eligible AML. Upon completion of this activity, participants should be better able to: Identify baseline clinical and molecular factors that can inform prognosis and treatment decisions for transplant-eligible patients with acute myeloid leukemia (AML), Employ modern therapeutics as components of personalized induction, consolidation, and maintenance/post-remission regimens for transplant-eligible patients with AML in accordance with updated safety and efficacy evidence and current guidelines, Integrate novel therapeutics into the management of patients with relapsed/refractory (R/R) AML, including as pre-transplant conditioning or as salvage options post-HCT.
Go online to PeerView.com/HJG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. New science has dramatically altered the current clinical consensus on personalized care for HCT-eligible AML patients and supported the use of a variety of options (depending on a patient's baseline characteristics). In this activity from the 2022 Tandem meetings, our expert panelists use a case-based format to tackle these new developments and provide instruction on how to integrate novel targeted, HMA, and antibody-based options into the management of HCT-eligible AML. Throughout, they provide insights on how to choose appropriate induction, conditioning, post-remission, and maintenance options, as well as discuss treatment plans for relapsed/refractory disease. Watch this program to see how novel therapeutics are changing paradigms and challenging long-standing practices in the management of HCT-eligible AML. Upon completion of this activity, participants should be better able to: Identify baseline clinical and molecular factors that can inform prognosis and treatment decisions for transplant-eligible patients with acute myeloid leukemia (AML), Employ modern therapeutics as components of personalized induction, consolidation, and maintenance/post-remission regimens for transplant-eligible patients with AML in accordance with updated safety and efficacy evidence and current guidelines, Integrate novel therapeutics into the management of patients with relapsed/refractory (R/R) AML, including as pre-transplant conditioning or as salvage options post-HCT.
Go online to PeerView.com/HJG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. New science has dramatically altered the current clinical consensus on personalized care for HCT-eligible AML patients and supported the use of a variety of options (depending on a patient's baseline characteristics). In this activity from the 2022 Tandem meetings, our expert panelists use a case-based format to tackle these new developments and provide instruction on how to integrate novel targeted, HMA, and antibody-based options into the management of HCT-eligible AML. Throughout, they provide insights on how to choose appropriate induction, conditioning, post-remission, and maintenance options, as well as discuss treatment plans for relapsed/refractory disease. Watch this program to see how novel therapeutics are changing paradigms and challenging long-standing practices in the management of HCT-eligible AML. Upon completion of this activity, participants should be better able to: Identify baseline clinical and molecular factors that can inform prognosis and treatment decisions for transplant-eligible patients with acute myeloid leukemia (AML), Employ modern therapeutics as components of personalized induction, consolidation, and maintenance/post-remission regimens for transplant-eligible patients with AML in accordance with updated safety and efficacy evidence and current guidelines, Integrate novel therapeutics into the management of patients with relapsed/refractory (R/R) AML, including as pre-transplant conditioning or as salvage options post-HCT.
Go online to PeerView.com/HJG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. New science has dramatically altered the current clinical consensus on personalized care for HCT-eligible AML patients and supported the use of a variety of options (depending on a patient's baseline characteristics). In this activity from the 2022 Tandem meetings, our expert panelists use a case-based format to tackle these new developments and provide instruction on how to integrate novel targeted, HMA, and antibody-based options into the management of HCT-eligible AML. Throughout, they provide insights on how to choose appropriate induction, conditioning, post-remission, and maintenance options, as well as discuss treatment plans for relapsed/refractory disease. Watch this program to see how novel therapeutics are changing paradigms and challenging long-standing practices in the management of HCT-eligible AML. Upon completion of this activity, participants should be better able to: Identify baseline clinical and molecular factors that can inform prognosis and treatment decisions for transplant-eligible patients with acute myeloid leukemia (AML), Employ modern therapeutics as components of personalized induction, consolidation, and maintenance/post-remission regimens for transplant-eligible patients with AML in accordance with updated safety and efficacy evidence and current guidelines, Integrate novel therapeutics into the management of patients with relapsed/refractory (R/R) AML, including as pre-transplant conditioning or as salvage options post-HCT.
Go online to PeerView.com/HJG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. New science has dramatically altered the current clinical consensus on personalized care for HCT-eligible AML patients and supported the use of a variety of options (depending on a patient's baseline characteristics). In this activity from the 2022 Tandem meetings, our expert panelists use a case-based format to tackle these new developments and provide instruction on how to integrate novel targeted, HMA, and antibody-based options into the management of HCT-eligible AML. Throughout, they provide insights on how to choose appropriate induction, conditioning, post-remission, and maintenance options, as well as discuss treatment plans for relapsed/refractory disease. Watch this program to see how novel therapeutics are changing paradigms and challenging long-standing practices in the management of HCT-eligible AML. Upon completion of this activity, participants should be better able to: Identify baseline clinical and molecular factors that can inform prognosis and treatment decisions for transplant-eligible patients with acute myeloid leukemia (AML), Employ modern therapeutics as components of personalized induction, consolidation, and maintenance/post-remission regimens for transplant-eligible patients with AML in accordance with updated safety and efficacy evidence and current guidelines, Integrate novel therapeutics into the management of patients with relapsed/refractory (R/R) AML, including as pre-transplant conditioning or as salvage options post-HCT.
Go online to PeerView.com/HJG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. New science has dramatically altered the current clinical consensus on personalized care for HCT-eligible AML patients and supported the use of a variety of options (depending on a patient's baseline characteristics). In this activity from the 2022 Tandem meetings, our expert panelists use a case-based format to tackle these new developments and provide instruction on how to integrate novel targeted, HMA, and antibody-based options into the management of HCT-eligible AML. Throughout, they provide insights on how to choose appropriate induction, conditioning, post-remission, and maintenance options, as well as discuss treatment plans for relapsed/refractory disease. Watch this program to see how novel therapeutics are changing paradigms and challenging long-standing practices in the management of HCT-eligible AML. Upon completion of this activity, participants should be better able to: Identify baseline clinical and molecular factors that can inform prognosis and treatment decisions for transplant-eligible patients with acute myeloid leukemia (AML), Employ modern therapeutics as components of personalized induction, consolidation, and maintenance/post-remission regimens for transplant-eligible patients with AML in accordance with updated safety and efficacy evidence and current guidelines, Integrate novel therapeutics into the management of patients with relapsed/refractory (R/R) AML, including as pre-transplant conditioning or as salvage options post-HCT.
Go online to PeerView.com/HJG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. New science has dramatically altered the current clinical consensus on personalized care for HCT-eligible AML patients and supported the use of a variety of options (depending on a patient's baseline characteristics). In this activity from the 2022 Tandem meetings, our expert panelists use a case-based format to tackle these new developments and provide instruction on how to integrate novel targeted, HMA, and antibody-based options into the management of HCT-eligible AML. Throughout, they provide insights on how to choose appropriate induction, conditioning, post-remission, and maintenance options, as well as discuss treatment plans for relapsed/refractory disease. Watch this program to see how novel therapeutics are changing paradigms and challenging long-standing practices in the management of HCT-eligible AML. Upon completion of this activity, participants should be better able to: Identify baseline clinical and molecular factors that can inform prognosis and treatment decisions for transplant-eligible patients with acute myeloid leukemia (AML), Employ modern therapeutics as components of personalized induction, consolidation, and maintenance/post-remission regimens for transplant-eligible patients with AML in accordance with updated safety and efficacy evidence and current guidelines, Integrate novel therapeutics into the management of patients with relapsed/refractory (R/R) AML, including as pre-transplant conditioning or as salvage options post-HCT.
Go online to PeerView.com/HJG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. New science has dramatically altered the current clinical consensus on personalized care for HCT-eligible AML patients and supported the use of a variety of options (depending on a patient's baseline characteristics). In this activity from the 2022 Tandem meetings, our expert panelists use a case-based format to tackle these new developments and provide instruction on how to integrate novel targeted, HMA, and antibody-based options into the management of HCT-eligible AML. Throughout, they provide insights on how to choose appropriate induction, conditioning, post-remission, and maintenance options, as well as discuss treatment plans for relapsed/refractory disease. Watch this program to see how novel therapeutics are changing paradigms and challenging long-standing practices in the management of HCT-eligible AML. Upon completion of this activity, participants should be better able to: Identify baseline clinical and molecular factors that can inform prognosis and treatment decisions for transplant-eligible patients with acute myeloid leukemia (AML), Employ modern therapeutics as components of personalized induction, consolidation, and maintenance/post-remission regimens for transplant-eligible patients with AML in accordance with updated safety and efficacy evidence and current guidelines, Integrate novel therapeutics into the management of patients with relapsed/refractory (R/R) AML, including as pre-transplant conditioning or as salvage options post-HCT.
PeerView Immunology & Transplantation CME/CNE/CPE Audio Podcast
Go online to PeerView.com/HJG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. New science has dramatically altered the current clinical consensus on personalized care for HCT-eligible AML patients and supported the use of a variety of options (depending on a patient's baseline characteristics). In this activity from the 2022 Tandem meetings, our expert panelists use a case-based format to tackle these new developments and provide instruction on how to integrate novel targeted, HMA, and antibody-based options into the management of HCT-eligible AML. Throughout, they provide insights on how to choose appropriate induction, conditioning, post-remission, and maintenance options, as well as discuss treatment plans for relapsed/refractory disease. Watch this program to see how novel therapeutics are changing paradigms and challenging long-standing practices in the management of HCT-eligible AML. Upon completion of this activity, participants should be better able to: Identify baseline clinical and molecular factors that can inform prognosis and treatment decisions for transplant-eligible patients with acute myeloid leukemia (AML), Employ modern therapeutics as components of personalized induction, consolidation, and maintenance/post-remission regimens for transplant-eligible patients with AML in accordance with updated safety and efficacy evidence and current guidelines, Integrate novel therapeutics into the management of patients with relapsed/refractory (R/R) AML, including as pre-transplant conditioning or as salvage options post-HCT.
PeerView Immunology & Transplantation CME/CNE/CPE Video Podcast
Go online to PeerView.com/HJG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. New science has dramatically altered the current clinical consensus on personalized care for HCT-eligible AML patients and supported the use of a variety of options (depending on a patient's baseline characteristics). In this activity from the 2022 Tandem meetings, our expert panelists use a case-based format to tackle these new developments and provide instruction on how to integrate novel targeted, HMA, and antibody-based options into the management of HCT-eligible AML. Throughout, they provide insights on how to choose appropriate induction, conditioning, post-remission, and maintenance options, as well as discuss treatment plans for relapsed/refractory disease. Watch this program to see how novel therapeutics are changing paradigms and challenging long-standing practices in the management of HCT-eligible AML. Upon completion of this activity, participants should be better able to: Identify baseline clinical and molecular factors that can inform prognosis and treatment decisions for transplant-eligible patients with acute myeloid leukemia (AML), Employ modern therapeutics as components of personalized induction, consolidation, and maintenance/post-remission regimens for transplant-eligible patients with AML in accordance with updated safety and efficacy evidence and current guidelines, Integrate novel therapeutics into the management of patients with relapsed/refractory (R/R) AML, including as pre-transplant conditioning or as salvage options post-HCT.
© 2020-2025 Ivy Podcast Discovery LLC
